Advertisement

Acetaminophen and Codeine Phosphate 300 mg/30 mg Tablets

[10 February 2016]

Products Affected - Description

Acetaminophen and Codeine tablet, Aurobindo
300 mg/ 30 mg, 100 count (NDC 13170-0059-01) - discontinued

Acetaminophen and codeine phosphate tablets, Mylan Institutional
300 mg/ 30 mg, unit-dose 100 count (NDC 51079-0161-21) - discontinued
 

Reason for the Shortage

  • Mallinckrodt has acetaminophen and codeine tablets available but allocates product to wholesalers based on previous order history.
  • Qualitest will not provide shortage information for any of their products because they consider the information to be proprietary.

Available Products

Tylenol with Codeine #3 tablet, Janssen
300 mg/ 30 mg, 100 count (NDC 50458-0513-60)
300 mg/ 30 mg, 1000 count (NDC 50458-0513-80)
 
Acetaminophen and codeine phosphate tablets, Amneal
300 mg/30 mg, 100 count (NDC 65162-0033-10)
300 mg/30 mg, 1000 count (NDC 65162-0033-11)
 
Acetaminophen and Codeine tablet, Aurobindo
300 mg/ 30 mg, 1000 count (NDC 13107-0059-99)
 
Acetaminophen and Codeine tablet, Mallinckrodt
300 mg/ 30 mg, 30 count (NDC 00406-0484-03)
300 mg/ 30 mg, 100 count (NDC 00406-0484-01)
300 mg/ 30 mg, unit-dose 100 count (NDC 00406-0484-62)
300 mg/ 30 mg, 1000 count (NDC 00406-0484-10)
 
Acetaminophen and Codeine tablet, Mylan Institutional
300 mg/ 30 mg, unit-dose 100 count (NDC 51079-0161-20)
 
Acetaminophen and codeine phosphate tablets, Teva
300 mg/30 mg, 100 count (NDC 00093-0150-01)
300 mg/30 mg, 1000 count (NDC 00093-0150-10)

Estimated Resupply Dates

Mallinckrodt has acetaminophen and codeine 300 mg/30 mg tablets available and allocated product monthly to wholesalers based on previous order history.

Related Shortages

Updated

February 10, 2016; December 16, October 29, September 3, August 12, July 20, June 18, April 22, March 20, February 13, January 7, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing